Anemias excluding cobalamin and folate deficiencies

In Situ Synthesis of Zero-Valent Iron-Decorated Lignite Carbon for Aqueous Heavy Metal Remediation

Lignite’s large abundance, physicochemical properties and low cost are attractive for industrial wastewater remediation. However, directly applying lignite for wastewater treatment suffers low efficiency. Here, we synthesize highly efficient zero-valent iron (ZVI)-decorated lignite carbon through the in-situ carbonization of a lignite and FeCl2 mixture for heavy metal removal. The effect of carbonization temperature on the morphology, structure and crystallite phases of ZVI-decorated lignite carbons (ZVI-LXs) was investigated. At an optimized temperature (i.e., 1000 °C), ZVI particles were found evenly distributed on the lignite matrix with the particles between 20 to 190 nm. Moreover, ZVI particles were protected by a graphene shell that was formed in situ during the carbonization. The synthesized ZVI-L1000 exhibited higher Cu2+, Pb2+ and Cd2+ stripping capacities than pristine lignite in a wide pH range of 2.2–6.3 due to the surface-deposited ZVI particles. The maximum Langmuir adsorption capacities of ZVI-L1000 for Cd2+, Pb2+ and Cu2+ were 38.3, 55.2 and 42.5 mg/g at 25 °C, respectively, which were 7.8, 4.5 and 10.6 times greater than that of pristine lignite, respectively. ZVI-L1000 also exhibited a fast metal removal speed (~15 min), which is ideal for industrial wastewater treatment. The pseudo-second-order model fits well with all three adsorptions, indicating that chemical forces control their rate-limiting adsorption steps. The reduction mechanisms of ZVI-L1000 for heavy metals include reduction, precipitation and complexation.

A Blood Pact: the Significance and Implications of eIF4E on Lymphocytic Leukemia

Elevated levels of eukaryotic initiation factor 4E (eIF4E) are implicated in neoplasia, with cumulative evidence pointing to its role in the etiopathogenesis of hematological diseases. As a node of convergence for several oncogenic signaling pathways, eIF4E has attracted a great deal of interest from biologists and clinicians whose efforts have been targeting this translation factor and its biological circuits in the battle against leukemia. The role of eIF4E in myeloid leukemia has been ascertained and drugs targeting its functions have found their place in clinical trials. Little is known, however, about the pertinence of eIF4E to the biology of lymphocytic leukemia and a paucity of literature is available in this regard that prospectively evaluates the topic to guide practice in hematological cancer. A comprehensive analysis on the significance of eIF4E translation factor in the clinical picture of leukemia arises, therefore, as a compelling need. This review presents aspects of eIF4E involvement in the realm of the lymphoblastic leukemia status; translational control of immunological function via eIF4E and the state-of-the-art in drugs will also be outlined.